Exploring the Effectiveness of AI Generative Models for Diabetic Patients
NCT ID: NCT05883072
Last Updated: 2023-06-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
300 participants
OBSERVATIONAL
2023-01-05
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Application of an AI-driven Multimodal Predictive Model for Cognitive Impairment in Patients With Type 2 Diabetes Mellitus
NCT07128186
The Effect of Remote SMBG Combined With the Application of APP on the Improvement of T2DM Management in the Community
NCT03588000
Use of AI in Cardiometabolic Risk Prediction in Asian Indians
NCT05939869
Analysis of Relevant Influencing Factors of Glycemic Control in Patients With Diabetes
NCT05854862
Therapeutic Effect of Dapagliflozin Combined With CSII on Newly Diagnosed Type 2 Diabetes Mellitus
NCT04120623
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The recent advancements in Generative Artificial Intelligence-based chatbots have demonstrated their efficacy as intelligent assistants across various aspects of human life. In this study, we aim to assess the effectiveness of these Language Models in assisting patients. Our research plan entails the interaction between patients and chatbots like ChatGPT, both with and without human support, followed by evaluations of these interactions by specialists. Additionally, we will gather feedback from patients regarding their experiences and perceptions of the chatbot interactions.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intervention
Patients will be provided access to Chatbot to enquire their querries regarding diabetic complications.
Exploring AI-Chatbot
All participants will be provided access to AI-Chatbot and will be asked to enquire their daily life problems related to diabetes. They will also be asked to review the replies of the Chatbot after their interaction.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Exploring AI-Chatbot
All participants will be provided access to AI-Chatbot and will be asked to enquire their daily life problems related to diabetes. They will also be asked to review the replies of the Chatbot after their interaction.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Adults (18 years or older)
* Diabetic Patient
Exclusion Criteria
* Individuals who are not yet adults (infants, children, teenagers)
* Prisoners
18 Years
100 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pakistan Council of Scientific and Industrial Research
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ghulam Mustafa
Role: PRINCIPAL_INVESTIGATOR
Pakistan Council of Scientific and Industrial Research
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CDLE, PCSIR Lbas Complex
Karachi, Sindh, Pakistan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AI Chatbot Evaluation
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.